贵州益佰制药股份有限公司 董事会议事规则 （2023 年 11 月修订） 第一章 总则 第一条 为规范贵州益佰制药股份有限公司（以下简称"公司"）董事会的议 事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事会规范运作 和科学决策水平，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》、中国证监会《上市公司治理准则》、《上海证券交易所股票 上市规则》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》以及 《贵州益佰制药股份有限公司章程》（以下简称"《公司章程》"）等有关规定， 并结合公司实际情况，制订本规则。 第二条 董事会应当在《公司法》等法律、行政法规、部门规章及规范性文件 和《公司章程》等有关规定的范围内行使职权。 第三条 公司设董事会，对股东大会负责，董事会下设董事会办公室，处理董 事会日常事务。董事会秘书或者证券事务代表兼任董事会办公室负责人，保管董 事会和董事会办公室印章。 第四条 董事会下设董事会办公室，处理董事会日常事务。 公司董事会设立审计委员会，并根据需要设立战略、提名、薪酬与考核等相 关专门委员会。专门委员会对董事会负责，依照公司章程 ...

证券代码：600594 证券简称：益佰制药 公告编号：2023-032 贵州益佰制药股份有限公司 股票质押式回购交易延期购回公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东窦啟玲女士持有贵州益佰制药股份有限公司（以下简称"公司"） 股份数量 185,457,636 股，占公司总股本的 23.42%，控股股东窦啟玲女士持有 公司股份累计质押数量为 113,295,500 股，占其持股数量的 61.09%，占公司总 股本的 14.31%。 控股股东窦啟玲女士及其一致行动人窦雅琪女士累计质押股份数量为 113,295,500 股，占窦啟玲女士及其一致行动人窦雅琪女士合计所持公司股份的 61.00%，占公司总股本的 14.31%。 一、本次股份质押延期购回情况 近日，公司接到控股股东窦啟玲女士的通知，获悉其将所持有的公司部分股 份办理了股票质押延期购回业务，具体情况如下： 被质押股份不存在被用作重大资产重组业绩补偿等事项的担保或其他保障 用途情况。 二、股东累计质押股份情况 | | | | | | | | ...

Financial Performance - The company's operating revenue for Q3 2023 was CNY 657,132,885, representing a year-over-year increase of 0.61%[4] - The net profit attributable to shareholders for Q3 2023 was CNY 41,963,911.92, a decrease of 39.32% compared to the same period last year[4] - The basic earnings per share for Q3 2023 was CNY 0.053, down 39.08% year-over-year[5] - The net profit attributable to shareholders for the year-to-date was CNY 169,869,961.21, down 13.33% compared to the same period last year[4] - The company reported a decrease of 7.64% in net profit after deducting non-recurring gains and losses for the year-to-date, totaling CNY 142,946,602.53[4] - The net profit for Q3 2023 was CNY 161,499,907.31, a decrease of 16.8% compared to CNY 194,249,563.62 in Q3 2022[21] - The total profit for Q3 2023 was CNY 194,907,546.17, down from CNY 239,833,220.77 in the same period last year, representing a decline of 18.7%[21] - The basic and diluted earnings per share for Q3 2023 were CNY 0.215, compared to CNY 0.247 in Q3 2022, reflecting a decrease of 13.0%[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,901,384,082.50, reflecting a slight increase of 0.73% from the end of the previous year[5] - As of September 30, 2023, the company's total current assets amounted to RMB 2,137,225,252.45, an increase from RMB 2,040,631,267.51 at the end of 2022, reflecting a growth of approximately 4.8%[16] - The total equity attributable to shareholders at the end of the reporting period was CNY 3,214,168,065.93, an increase of 5.58% from the previous year-end[5] - The company's total assets as of the end of the third quarter of 2023 amounted to ¥4,901,384,082.50, compared to ¥4,865,807,509.44 at the end of the same period in 2022, showing an increase of about 0.7%[18] - Total liabilities decreased to ¥1,549,886,283.75 in 2023 from ¥1,675,881,347.56 in 2022, representing a decline of approximately 7.5%[18] - The total non-current assets increased to CNY 2,829,498,234.86, reflecting an adjustment of CNY 4,321,992.93[31] - Current liabilities totaled CNY 1,172,715,463.95, remaining stable compared to previous periods[32] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was CNY 343,155,292.85, showing an increase of 10.88%[5] - The cash flow from investing activities for the first nine months of 2023 was negative CNY 102,439,355.09, an improvement from negative CNY 247,113,792.77 in the same period of 2022[26] - Cash and cash equivalents at the end of Q3 2023 totaled CNY 683,933,062.18, down from CNY 900,905,459.29 at the end of Q3 2022, indicating a decrease of 24.1%[27] Shareholder Information - The top shareholder, Dou Qiling, holds 185,457,636 shares, representing 23.42% of the total shares[14] - The second-largest shareholder, Zhang Biling, holds 20,971,344 shares, accounting for 2.65% of the total shares[14] - The company has not disclosed any related party relationships among the top ten shareholders[14] Government Support and Non-Recurring Gains - The company received government subsidies amounting to CNY 6,024,954.46 during the reporting period, contributing to its non-recurring gains[7] Future Outlook and Strategic Initiatives - The company has not provided any specific guidance for future performance or new product developments in the current report[16] - The company plans to continue focusing on market expansion and new product development as part of its strategic initiatives moving forward[20] - The company is focused on enhancing its financial position and exploring new strategies for market expansion and product development[34] Operating Costs and Expenses - Total operating costs for the first three quarters of 2023 were ¥1,930,208,223.55, compared to ¥1,901,760,985.35 in 2022, indicating an increase of about 1.5%[20] - The company incurred operating expenses of CNY 2,002,763,789.31 in Q3 2023, compared to CNY 1,939,622,241.77 in Q3 2022, reflecting an increase of 3.2%[26] - Research and development expenses decreased to ¥73,852,804.23 in 2023 from ¥78,838,392.66 in 2022, reflecting a reduction of approximately 6.3%[20] - The company reported a decrease in financial expenses to ¥11,084,045.56 in 2023 from ¥24,737,766.33 in 2022, indicating a reduction of approximately 55.2%[20]

证券代码：600594 证券简称：益佰制药 公告编号：2023-031 贵州益佰制药股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 投资者可于 2023 年 10 月 27 日（星期五）16:00 前登录上证路演中心网站 首页点击"提问预征集"栏目或通过公司邮箱（600594@gz100.cn）进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 贵州益佰制药股份有限公司（以下简称"公司"）拟于 2023 年 10 月 27 日在 上海证券交易所网站（http://www.sse.com.cn/）披露《贵州益佰制药股份有限 公司 2023 年第三季度报告》，为便于广大投资者更全面深入地了解公司 2023 年 第三季度财务状况、经营成果，公司计划于 2023 年 10 月 30 日（星期一）15:00- 16:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、业绩说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2023 年第三季度的财务 状况及经营成果的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、业 ...

北京市君致律师事务所 关于贵州益佰制药股份有限公司 2023 年第三次临时股东大会 法 律 意 见 书 北京 · 东城区北三环东路 36 号环球贸易中心 B 座 11 层 100013 电话（Te1）: 010-52213236/52213237/52213238/52213239 北京市君致律师事务所 关于贵州益佰制药股份有限公司 2023 年第三次临时股东大会 法律意见书 致: 贵州益佰制药股份有限公司 北京市君致律师事务所(以下简称"本所")接受贵州益佰制药股份有限公 司(以下简称"益佰制药"或"公司")的委托，指派律师出席益佰制药 2023 年 第三次临时股东大会(以下简称"本次股东大会")。根据《中华人民共和国证券 法》(以下简称"《证券法》")、《中华人民共和国公司法》(以下简称"《公司法》") 和《上市公司股东大会规则》(以下简称"《股东大会规则》)、《上海证券交易 所上市公司自律监管指引第 1 号一规范运作》(以下简称"《自律监管指引第 1 号》")等法律、法规和其他有关规范性文件及《贵州益佰制药股份有限公司章程》 (以下简称"《公司章程》"的规定,本所律师就本次股东大会的召集、召开程 序、出 ...

证券代码：600594 证券简称：益佰制药 公告编号：2023-030 2023 年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2023 年 9 月 5 日 (二)股东大会召开的地点：贵州益佰制药股份有限公司行政楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 17 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 198,003,245 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 25.0027 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 贵州益佰制药股份有限公司 二、议案审议情况 (一)非累积投票议案 本次股东大会的表决方式符合《公司法》及《公司章程》的规定，股东大会 由公司董事长窦啟玲女士主持。 (五)公司董事、监事和董 ...

贵州益佰制药股份有限公司 2023 年第三次临时股东大会会议资料 贵州益佰制药股份有限公司 600594 2023年第三次临时股东大会会议资料 1/4 2/4 贵州益佰制药股份有限公司 2023 年第三次临时股东大会会议资料 贵州益佰制药股份有限公司 贵州益佰制药股份有限公司 2023 年第三次临时股东大会会议资料 目录 | 贵州益佰制药股份有限公司 2023 年第三次临时股东大会会议议程 3 | | --- | | 议案一：《关于购买公司董监高责任险的议案》 4 | 2023 年第三次临时股东大会会议议程 会议方式：本次股东大会采用现场投票和网络投票相结合的方式召开 现场会议时间：2023年9月5日 星期二 10:00 交易系统投票平台投票时间：2023年9月5日 星期二 9:15-9:25，9:30-11:30， 13:00-15:00 互联网投票平台投票时间：2023年9月5日 星期二 9:15-15:00 现场会议地点：贵州益佰制药股份有限公司行政楼会议室 主持人：董事长窦啟玲女士 出席对象：截止2023年8月29日下午交易结束后在中国证券登记结算有限责任公 司上海分公司登记在册的本公司股东及股东代理 ...

重要内容提示： 会议召开时间：2023 年 9 月 4 日 星期一 15:00-16:00 证券代码：600594 证券简称：益佰制药 公告编号：2023-029 贵州益佰制药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （三）会议召开方式：上证路演中心网络互动方式 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow. sseinfo.com/） 会议召开方式：上证路演中心网络互动方式 投资者可于 2023 年 8 月 28 日（星期一）至 9 月 1 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （600594@gz100.cn）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 贵州益佰制药股份有限公司（以下简称"公司"）已于 2023 年 8 月 18 日在 上海证券交易所网站（http://www.sse.com.cn/）披露了《贵州益佰制药股份有 限公司 2023 年半年度 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,479,701,367.04, representing a 2.33% increase compared to CNY 1,446,063,415.53 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was CNY 127,906,049.29, a slight increase of 0.84% from CNY 126,841,647.60 year-on-year[22]. - The net profit after deducting non-recurring gains and losses decreased by 12.28%, amounting to CNY 104,065,059.82 compared to CNY 118,626,715.03 in the previous year[22]. - The net cash flow from operating activities increased significantly by 76.36%, reaching CNY 202,303,020.59, up from CNY 114,708,370.37 in the same period last year[22]. - The total assets at the end of the reporting period were CNY 4,999,877,498.09, reflecting a 2.76% increase from CNY 4,865,807,509.44 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company increased by 4.22%, totaling CNY 3,172,547,778.33 compared to CNY 3,044,226,375.16 at the end of the previous year[22]. - The basic earnings per share for the first half of 2023 was CNY 0.162, a 1.25% increase from CNY 0.160 in the same period last year[23]. - The weighted average return on net assets increased by 0.559 percentage points to 4.115% compared to 3.556% in the previous year[23]. Operational Highlights - The company operates in the pharmaceutical industry, focusing on the full supply chain from raw material cultivation to drug production and sales[29]. - Key products include chemotherapy drugs, cardiovascular treatments, and traditional Chinese medicine, with a strong emphasis on innovation and quality improvement[29]. - The healthcare segment includes the operation of comprehensive hospitals and specialized cancer treatment centers, enhancing service quality[30]. - The company is expanding its health product line, focusing on traditional medicine and leveraging both direct sales and e-commerce channels[31]. - The procurement strategy emphasizes quality and cost control through a centralized purchasing platform and strict supplier management[33]. - The production process adheres to GMP standards, ensuring product safety and quality through rigorous monitoring and innovation[34]. - The sales strategy focuses on market demand and customer service, with a strong emphasis on building a dedicated sales team and optimizing market penetration[35]. - The company is transforming from a modern traditional Chinese medicine manufacturer to a comprehensive pharmaceutical enterprise that includes chemical drugs, modern traditional Chinese medicine, and biological drugs[37]. Market Position and Strategy - The company has a well-established product layout in key therapeutic areas such as oncology, cardiovascular, gynecology, pediatrics, orthopedics, and respiratory diseases, with significant market shares for core products like Loxapine and Aidi[39]. - The company emphasizes continuous innovation through independent research and development, collaborative research, and acquisitions to obtain new products[37]. - The company is actively expanding its medical and health sectors while maintaining a focus on its pharmaceutical industrial segment, driving sustainable development[37]. - The Chinese pharmaceutical market is expected to continue expanding due to increasing healthcare demands driven by an aging population and rising living standards[41]. - The company has been recognized as one of the "Top 100 Pharmaceutical Enterprises in China" for 18 consecutive years, reflecting its strong market position and credibility[38]. - The company is committed to enhancing its core competitiveness by improving production management systems and cost control measures[37]. - The ongoing pressure on medical insurance funds highlights the need for the company to adapt to stricter cost control policies in the pharmaceutical industry[44]. Research and Development - The company has applied for 522 patents, including 330 invention patents, with 231 patents authorized and maintained as valid[52]. - The company is focusing on innovation and R&D, with ongoing projects including the production research of pearl pills and the registration applications for YBR-6002 and Pulesaf injection[63]. - The company completed the registration of 103 new varieties, including 81 national standard varieties and 22 provincial standard varieties, by June 30, 2023[64]. - The company plans to enhance drug research and development through self-research, joint development, and acquisitions, focusing on innovative products and improving research efficiency[71]. - The company is advancing the application for the new drug Pearl Drop Pills and continuing the development of other projects like YBR-6002 and YBR-6005[72]. Environmental Compliance - The company has implemented a comprehensive quality control system to ensure compliance with new industry standards and regulations throughout the drug development process[93]. - The company has established a wastewater treatment facility with a capacity of 2,000 m³/d, and additional facilities at various sites, including 50 m³/d and 800 m³/d at different plants[112]. - The company has implemented measures to ensure compliance with environmental standards, including the "Comprehensive Emission Standards for Wastewater" and "Standards for Emission of Air Pollutants"[107]. - The company has established a waste management strategy, collaborating with local waste treatment companies for solid and hazardous waste disposal[106]. - The company has successfully implemented a "spray adsorption + UV photolysis" and "spray adsorption + oxidation absorption" process for waste gas treatment[112]. - The company has established emergency response plans for environmental incidents, with key risk sources identified including chemical leaks and wastewater pollution[116]. - The company has not experienced any major environmental pollution incidents during the reporting period and complies with all relevant environmental laws and regulations[113]. Shareholder and Governance - The total number of ordinary shareholders as of the end of the reporting period is 59,720[138]. - The largest shareholder, Dou Qiling, holds 185,457,636 shares, representing 23.42% of the total shares, with 113,295,500 shares pledged[139]. - There are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[130]. - The company has not provided any guarantees for shareholders, actual controllers, or their related parties[134]. - The company has held two shareholder meetings in 2023, addressing key governance issues and approving various proposals related to financial reports and board elections[98]. - The company has experienced changes in its board and management personnel, with several new appointments and departures in key positions[99]. Future Outlook - The company plans to continue optimizing its medical assets and explore new products and technologies to enhance profitability and sustainable growth[79]. - The company aims to implement a high-quality comprehensive management approach to improve production capacity and product quality, ensuring compliance and risk management[75]. - The company plans to continue its market expansion and product development strategies to enhance future growth prospects[186].

证券代码：600594 证券简称：益佰制药 公告编号：2023-026 贵州益佰制药股份有限公司 关于购买公司董监高责任险的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步完善贵州益佰制药股份有限公司（以下简称"公司"）风险管理体 系，降低公司运营风险，促进公司董事、监事及高级管理人员在其职责范围内充 分行使权利、履行职责，保障公司和全体股东的权益，公司拟为公司全体董事、 监事及高级管理人员（以下简称"全体董监高"）购买责任险。根据《上海证券 交易所股票上市规则》、《上市公司治理准则》等相关规定，公司于 2023 年 8 月 16 日召开公司第八届董事会第二次会议、第八届监事会第二次会议，审议了《关 于购买公司董监高责任险的议案》。因该事项与公司全体董监高存在利害关系， 全体董事、监事在审议该事项时回避表决并直接提交公司 2023 年第三次临时股 东大会审议。独立董事对该事项发表了独立意见。现将相关事项公告如下： 一、董监高责任险投保方案： 1、投保人：贵州益佰制药股份有限公司 2、被保险人：公司及公司全体董事、 ...